Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRE Stock Forecast 2025-2026
$14.30
Current Price
$240.65M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRE Price Targets
+116.8%
To High Target of $31.00
+116.8%
To Median Target of $31.00
+116.8%
To Low Target of $31.00
PRE Price Momentum
+2.7%
1 Week Change
+10.6%
1 Month Change
+175.0%
1 Year Change
+146.6%
Year-to-Date Change
-20.5%
From 52W High of $17.99
+362.0%
From 52W Low of $3.10
📊 TOP ANALYST CALLS
Did PRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Prenetics is one of their latest high-conviction picks.
Latest PRE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PRE has a bullish consensus with a median price target of $31.00 (ranging from $31.00 to $31.00). The overall analyst rating is N/A (N/A/10). Currently trading at $14.30, the median forecast implies a 116.8% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRE Analyst Ratings
1
Buy
0
Hold
0
Sell
PRE Price Target Range
Low
$31.00
Average
$31.00
High
$31.00
Current: $14.30
Latest PRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 29, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $32.00 |
| Jan 16, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $9.00 |
| Dec 4, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $9.00 |
| Apr 4, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $9.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $4.00 |
| Sep 19, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $4.00 |
| Aug 22, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Jan 18, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Initiates | $7.00 |
| Jul 28, 2015 | Barclays | Overweight | Maintains | $140.00 | |
| Jul 9, 2015 | Deutsche Bank | Hold | Maintains | $6.10 | |
| Jun 18, 2015 | Keefe, Bruyette & Woods | Market Perform | Maintains | $140.00 | |
| May 13, 2015 | BMO Capital | Market Perform | Maintains | $137.50 | |
| May 6, 2015 | Deutsche Bank | Hold | Maintains | $6.50 | |
| Apr 22, 2015 | UBS | Neutral | Downgrade | $N/A | |
| Apr 20, 2015 | Deutsche Bank | Hold | Maintains | $130.00 | |
| Apr 17, 2015 | BMO Capital | Market Perform | Downgrade | $130.00 | |
| Mar 26, 2015 | BMO Capital | Outperform | Upgrade | $122.00 | |
| Feb 5, 2015 | JMP Securities | Market Perform | Downgrade | $N/A | |
| Jan 20, 2015 | Deutsche Bank | Hold | Maintains | $6.10 | |
| Jan 8, 2015 | Barclays | Overweight | Maintains | $125.00 |
Prenetics Global Limited (PRE) Competitors
The following stocks are similar to Prenetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Prenetics Global Limited (PRE) Financial Data
Prenetics Global Limited has a market capitalization of $240.65M with a P/E ratio of 1.1x. The company generates $77.08M in trailing twelve-month revenue with a -60.4% profit margin.
Revenue growth is +202.8% quarter-over-quarter, while maintaining an operating margin of -26.2% and return on equity of -30.1%.
Valuation Metrics
Market Cap
$240.65M
Enterprise Value
$169.58M
P/E Ratio
1.1x
PEG Ratio
0.0x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
+202.8%
Gross Margin
+59.5%
Operating Margin
-26.2%
Net Margin
-60.4%
EPS Growth
+202.8%
Financial Health
Cash/Price Ratio
+15.7%
Current Ratio
2.7x
Debt/Equity
1.3x
ROE
-30.1%
ROA
-14.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Prenetics Global Limited (PRE) Business Model
About Prenetics Global Limited
What They Do
Biotechnology company offering genetic testing services.
Business Model
Prenetics generates revenue through genetic and diagnostic testing services. By providing advanced technology solutions for personalized healthcare, the company helps individuals make informed health decisions, while also catering to businesses with their diagnostic offerings, particularly in response to public health needs.
Additional Information
Headquartered in Hong Kong, Prenetics has a global reach and emphasizes precision medicine. The company has made significant contributions during health crises, such as with COVID-19 testing kits, and continues to innovate through strategic partnerships in the healthcare and biotechnology sectors.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
285
CEO
Mr. Sheng Wu Yeung
Country
Hong Kong
IPO Year
2022
Website
www.prenetics.comPrenetics Global Limited (PRE) Latest News & Analysis
Latest News
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
17 days ago
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) announced that its executive leadership team has purchased common stock in the open market, indicating confidence in the company's performance.
Why It Matters
Executive leadership's open market purchases signal confidence in Prenetics' future performance, potentially boosting investor sentiment and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics Global Limited (NASDAQ: PRE) will participate in upcoming investor conferences, enhancing its visibility in the health sciences sector.
Why It Matters
Prenetics' participation in investor conferences can enhance visibility, attract potential investors, and signal growth opportunities, potentially impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cantor Fitzgerald maintains an Overweight rating for Prenetics (NASDAQ: PRE), projecting $217M in FY2026 revenue and a 12-month price target of $31, citing strong unit economics and financial strength.
Why It Matters
Strong unit economics and positive revenue forecasts enhance investor confidence in Prenetics, signaling growth potential and financial stability, crucial for stock valuation and investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics reported a 568% YoY revenue increase to $23.6M, with October's IM8 revenue at $9M. The company forecasts $180-$200M FY 2026 revenue and $300M ARR by year-end 2026.
Why It Matters
Surging revenue and strong growth projections indicate robust financial health, enhancing investor confidence. The earnings call and shareholder letter will provide further insights into future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prenetics Global Limited reported a 32% month-over-month revenue increase in October, projecting $10 million in monthly revenue by December 2025. IM8 reached $108 million in annualized recurring revenue.
Why It Matters
Prenetics' 32% month-over-month revenue growth signals strong market demand and potential for sustained performance, enhancing investor confidence in future profitability and growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
1 month ago
Quick Summary
Prenetics Global Limited acquired 100 Bitcoin for ~$10.96 million, following a $44 million equity offering. The company now holds a total of 378 BTC, valued at ~$46 million.
Why It Matters
Prenetics' acquisition of 100 Bitcoin signals a strategic move into digital assets, potentially increasing its market valuation and attracting investor interest amid rising Bitcoin prices.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRE Stock
What is Prenetics Global Limited's (PRE) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Prenetics Global Limited (PRE) has a median price target of $31.00. The highest price target is $31.00 and the lowest is $31.00.
Is PRE stock a good investment in 2026?
According to current analyst ratings, PRE has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRE stock?
Wall Street analysts predict PRE stock could reach $31.00 in the next 12 months. This represents a 116.8% increase from the current price of $14.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prenetics Global Limited's business model?
Prenetics generates revenue through genetic and diagnostic testing services. By providing advanced technology solutions for personalized healthcare, the company helps individuals make informed health decisions, while also catering to businesses with their diagnostic offerings, particularly in response to public health needs.
What is the highest forecasted price for PRE Prenetics Global Limited?
The highest price target for PRE is $31.00 from at , which represents a 116.8% increase from the current price of $14.30.
What is the lowest forecasted price for PRE Prenetics Global Limited?
The lowest price target for PRE is $31.00 from at , which represents a 116.8% increase from the current price of $14.30.
What is the overall PRE consensus from analysts for Prenetics Global Limited?
The overall analyst consensus for PRE is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $31.00.
How accurate are PRE stock price projections?
Stock price projections, including those for Prenetics Global Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 3:51 PM UTC